Key result
Orsiro biodegradable polymer stents show a 3.3% one-year device-oriented composite outcome rate in complex PCI.
Why the study?
The long-term efficacy and safety of Orsiro biodegradable polymer-coated sirolimus-eluting stents in complex PCI patients required evaluation as complex PCI is increasingly common.
Observational (n=784)
Yes
Bioresorbable polymer sirolimus-eluting stents show favorable 12-month safety and efficacy in complex PCI, with an overall device-oriented composite outcome rate of 3.3%.
May support Orsiro in complex PCI; leaves open randomized confirmation before practice change.
Background: The long-term efficacy and safety of Orsiro biodegradable polymer-coated sirolimus-eluting stents in patients undergoing percutaneous coronary intervention (PCI) has been established.Since complex PCI is becoming increasingly common, this study evaluated the efficacy and safety of Orsiro stents in complex PCI. Methods:The bioresorbable polymer sirolimus-eluting stents in a complex percutaneous coronary intervention population (BIO-REAL) registry is a prospective, single-arm, observational trial designed to evaluate the clinical outcomes of patients who receive Orsiro Biodegradable polymer drug-eluting stents implantation during complex PCI at 6 centers in the Republic of Korea.Complex PCI involves treating conditions such as multivessel disease, diffuse lesions, chronic total occlusion lesions, bifurcated lesions, small vessels, calcified lesions, in-stent restenosis (ISR) lesions, ostial lesions, or left main lesions.The primary endpoint of this study is the device-oriented composite outcome (DOCO), which includes cardiac death, target vessel-related myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) at 12 months.Results: The study included 784 patients presenting with 1,098 lesions.The average age of the participants was 66.7 ± 10.8 years, with 74.6% being male.The primary endpoint was reached in 3.3% of the patients, consisting of a cardiac death rate of 2.2%, a target vesselrelated MI rate of 0.6%, and a TLR rate of 0.9%.Incidence of the primary endpoint was notably higher among patients with acute MI, diabetes mellitus (DM), or chronic kidney disease (CKD).Regarding complex PCI components, the DOCO rate was elevated in cases involving ISR lesions (6.8%) and those with moderate-to-severe calcification (4.1%). Conclusions:The Orsiro stent demonstrated optimal efficacy and safety at 12 months in patients undergoing complex PCI.Outcomes were less favorable in patients with acute MI, DM, or CKD undergoing complex PCI.Additionally, ISR and calcified lesions were associated with an increased risk of unfavorable outcomes following PCI.
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2025) conducted an observational in Complex percutaneous coronary intervention (n=784). Orsiro biodegradable polymer sirolimus-eluting stent was evaluated on 12-month device-oriented composite outcome (DOCO) including cardiac death, target vessel-related MI, and clinically driven TLR. The Orsiro biodegradable polymer sirolimus-eluting stent demonstrated a 12-month device-oriented composite outcome rate of 3.3% in patients undergoing complex percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: